https://techworldisrael.com/article/906119994-mapi-pharma-to-present-efficacy-edss-data-from-glatiramer-acetate-depot-long-acting-injection-studies-in-relapsing-forms-of-multiple-sclerosis-rms Tech World Israel en PressRelease 2026-04-16T13:30:00+00:00 Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026 https://ml.globenewswire.com/media/a15e698a-0f26-4d44-bf6a-78b7ae34d25d/small/mapi-pharma-logo-png.png https://techworldisrael.com/article/906124031-inspira-completes-commercial-deployment-of-its-ame-system-at-a-tier-1-u-s-defense-entity Tech World Israel en PressRelease 2026-04-16T13:21:00+00:00 Inspira Completes Commercial Deployment of its AME System at a Tier-1 U.S. Defense Entity https://ml.globenewswire.com/media/6a4eabfe-c9ec-40d1-87fc-6f0d8e6e408c/small/screenshot-2025-04-02-at-19-21-06-png.png https://techworldisrael.com/article/905880212-orvida-pharma-formerly-kamari-pharma-announces-favorable-phase-1a-safety-data-for-km-023-a-potential-first-in-disease-oral-trpv3-inhibitor-and Tech World Israel en PressRelease 2026-04-15T11:00:00+00:00 Orvida Pharma (formerly Kamari Pharma) Announces Favorable Phase 1a Safety Data for KM-023, a Potential First-in-Disease Oral TRPV3 Inhibitor, and Initiation of Phase 1b Study in Patients with Olmsted Syndrome https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg